Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin

Rui Sasaki, Taku Fujimura, Chunbing Lyu, Setsuya Aiba

研究成果: Article査読

12 被引用数 (Scopus)

抄録

Enfortumab vedotin (EV) is a novel, fully humanized monoclonal antibody–drug conjugate composed of an anti-Nectin-4 antibody joined to monomethyl auristatin E. In this report, we described a case of a severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing in patients with metastatic urothelial cancer treated with EV. Because phase II and phase III clinical studies are ongoing, in the future, substantial amounts of EV are expected to be used for the treatment of metastatic urothelial cancer. Therefore, understanding the mechanisms of drug eruption caused by EV is important for oncologists as well as dermatologists.

本文言語English
ページ(範囲)1436-1438
ページ数3
ジャーナルJournal of Dermatology
47
12
DOI
出版ステータスPublished - 2020 12月
外部発表はい

ASJC Scopus subject areas

  • 皮膚病学

フィンガープリント

「Severe eczematoid and lichenoid eruption with full-thickness epidermal necrosis developing from metastatic urothelial cancer treated with enfortumab vedotin」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル